vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Idaho Strategic Resources, Inc. (IDR). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $14.6M, roughly 1.0× Idaho Strategic Resources, Inc.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs 1.8%, a 62.5% gap on every dollar of revenue. On growth, Idaho Strategic Resources, Inc. posted the faster year-over-year revenue change (92.0% vs 11.5%). Idaho Strategic Resources, Inc. produced more free cash flow last quarter ($8.2M vs $-2.0M). Over the past eight quarters, Idaho Strategic Resources, Inc.'s revenue compounded faster (57.2% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Idaho Strategic Resources, Inc.IDREarnings & Financial Report
Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.
CSBR vs IDR — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $14.6M |
| Net Profit | $268.0K | $9.4M |
| Gross Margin | 51.7% | 68.5% |
| Operating Margin | 1.2% | 62.4% |
| Net Margin | 1.8% | 64.3% |
| Revenue YoY | 11.5% | 92.0% |
| Net Profit YoY | -63.2% | 220.6% |
| EPS (diluted) | $0.02 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $14.6M | ||
| Q3 25 | $14.0M | $11.1M | ||
| Q2 25 | $12.4M | $9.5M | ||
| Q1 25 | $17.0M | $7.3M | ||
| Q4 24 | $13.5M | $7.6M | ||
| Q3 24 | $14.1M | $6.2M | ||
| Q2 24 | $14.0M | $6.1M | ||
| Q1 24 | $12.0M | $5.9M |
| Q4 25 | $268.0K | $9.4M | ||
| Q3 25 | $-436.0K | $3.0M | ||
| Q2 25 | $-1.8M | $2.8M | ||
| Q1 25 | $4.5M | $1.6M | ||
| Q4 24 | $728.0K | $2.9M | ||
| Q3 24 | $1.3M | $1.6M | ||
| Q2 24 | $-109.0K | $2.2M | ||
| Q1 24 | $-2.5M | $2.2M |
| Q4 25 | 51.7% | 68.5% | ||
| Q3 25 | 42.9% | 63.6% | ||
| Q2 25 | 41.1% | 57.8% | ||
| Q1 25 | 61.2% | 50.8% | ||
| Q4 24 | 44.9% | 53.3% | ||
| Q3 24 | 49.7% | 48.7% | ||
| Q2 24 | 48.2% | 50.2% | ||
| Q1 24 | 34.7% | 48.1% |
| Q4 25 | 1.2% | 62.4% | ||
| Q3 25 | -3.8% | 23.4% | ||
| Q2 25 | -16.2% | 26.6% | ||
| Q1 25 | 26.4% | 19.3% | ||
| Q4 24 | 5.4% | 36.2% | ||
| Q3 24 | 9.5% | 23.4% | ||
| Q2 24 | -1.9% | 34.2% | ||
| Q1 24 | -21.4% | 36.3% |
| Q4 25 | 1.8% | 64.3% | ||
| Q3 25 | -3.1% | 26.8% | ||
| Q2 25 | -14.9% | 29.2% | ||
| Q1 25 | 26.4% | 22.1% | ||
| Q4 24 | 5.4% | 38.5% | ||
| Q3 24 | 9.3% | 25.8% | ||
| Q2 24 | -0.8% | 35.2% | ||
| Q1 24 | -21.1% | 36.8% |
| Q4 25 | $0.02 | $0.62 | ||
| Q3 25 | $-0.03 | $0.20 | ||
| Q2 25 | $-0.12 | $0.20 | ||
| Q1 25 | $0.31 | $0.12 | ||
| Q4 24 | $0.05 | $0.21 | ||
| Q3 24 | $0.09 | $0.12 | ||
| Q2 24 | $-0.01 | $0.17 | ||
| Q1 24 | $-0.19 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | — |
| Total DebtLower is stronger | — | $2.3M |
| Stockholders' EquityBook value | $4.2M | $108.2M |
| Total Assets | $30.2M | $116.2M |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | — | ||
| Q3 25 | $10.3M | — | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.6M | $6.3M | ||
| Q1 24 | $4.5M | $5.3M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | — | $3.3M | ||
| Q1 25 | — | $3.7M | ||
| Q4 24 | — | $1.7M | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | — | $2.7M | ||
| Q1 24 | — | $3.3M |
| Q4 25 | $4.2M | $108.2M | ||
| Q3 25 | $3.5M | $74.3M | ||
| Q2 25 | $3.8M | $49.3M | ||
| Q1 25 | $5.5M | $39.8M | ||
| Q4 24 | $681.0K | $37.7M | ||
| Q3 24 | $-332.0K | $33.1M | ||
| Q2 24 | $-1.9M | $25.4M | ||
| Q1 24 | $-2.1M | $21.6M |
| Q4 25 | $30.2M | $116.2M | ||
| Q3 25 | $30.5M | $83.1M | ||
| Q2 25 | $32.3M | $57.7M | ||
| Q1 25 | $30.6M | $48.1M | ||
| Q4 24 | $25.2M | $44.0M | ||
| Q3 24 | $24.9M | $40.8M | ||
| Q2 24 | $26.1M | $32.2M | ||
| Q1 24 | $26.8M | $28.7M |
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.09× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.09× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $10.7M |
| Free Cash FlowOCF − Capex | $-2.0M | $8.2M |
| FCF MarginFCF / Revenue | -13.1% | 56.0% |
| Capex IntensityCapex / Revenue | 1.6% | 17.7% |
| Cash ConversionOCF / Net Profit | -6.47× | 1.15× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $12.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $10.7M | ||
| Q3 25 | $600.0K | $2.4M | ||
| Q2 25 | $6.9M | $3.5M | ||
| Q1 25 | $490.0K | $2.4M | ||
| Q4 24 | $-283.0K | $3.2M | ||
| Q3 24 | $311.0K | $2.5M | ||
| Q2 24 | $-1.8M | $2.6M | ||
| Q1 24 | $-919.0K | $2.6M |
| Q4 25 | $-2.0M | $8.2M | ||
| Q3 25 | $554.0K | $709.8K | ||
| Q2 25 | $6.6M | $2.5M | ||
| Q1 25 | $448.0K | $1.0M | ||
| Q4 24 | $-377.0K | $2.1M | ||
| Q3 24 | — | $1.9M | ||
| Q2 24 | $-1.8M | $2.4M | ||
| Q1 24 | $-1.0M | $2.3M |
| Q4 25 | -13.1% | 56.0% | ||
| Q3 25 | 4.0% | 6.4% | ||
| Q2 25 | 53.5% | 26.5% | ||
| Q1 25 | 2.6% | 13.8% | ||
| Q4 24 | -2.8% | 28.0% | ||
| Q3 24 | — | 30.4% | ||
| Q2 24 | -13.0% | 38.7% | ||
| Q1 24 | -8.4% | 38.3% |
| Q4 25 | 1.6% | 17.7% | ||
| Q3 25 | 0.3% | 15.3% | ||
| Q2 25 | 2.0% | 10.8% | ||
| Q1 25 | 0.2% | 19.4% | ||
| Q4 24 | 0.7% | 13.6% | ||
| Q3 24 | 0.0% | 9.8% | ||
| Q2 24 | 0.0% | 4.3% | ||
| Q1 24 | 0.8% | 5.5% |
| Q4 25 | -6.47× | 1.15× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.28× | ||
| Q1 25 | 0.11× | 1.50× | ||
| Q4 24 | -0.39× | 1.08× | ||
| Q3 24 | 0.24× | 1.56× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
IDR
Segment breakdown not available.
